Hopital Prive Saint Claude

At Hopital Prive Saint Claude the gastroenterology department is also conducting a study focused on heart failure with concurrent kidney impairment, aiming to test whether adding balcinrenone/dapagliflozin can lower the risk of cardiovascular death and related hospitalizations.

• Comparison of combination therapy versus standard dapagliflozin alone
• Assessment of reduction in heart‑failure events
• Evaluation of safety in patients with reduced kidney function

The trial involves two investigators and reflects the site’s commitment to advancing treatments for complex cardiovascular conditions.

Researchers are exploring a ctDNA‑guided adjuvant approach for stage II colon carcinoma, seeking to improve disease‑free survival by treating patients who test positive for circulating tumor DNA with FOLFOX6m chemotherapy.

• Use of circulating tumor DNA to personalize adjuvant therapy
• Targeted administration of intensified FOLFOX regimen
• Monitoring of recurrence risk after surgery

This study highlights the site’s innovative focus on molecular diagnostics within digestive oncology.

A separate trial evaluates first‑line treatment of microsatellite stable metastatic colorectal cancer with a high immune infiltrate, combining pembrolizumab immunotherapy with XELOX or FOLFOX chemotherapy and bevacizumab to increase the proportion of patients alive without disease progression at ten months.

• Integration of immunotherapy with standard chemotherapy
• Stratification based on tumor immune infiltrate
• Measurement of 10‑month progression‑free survival

The project underscores the collaborative effort of the site’s investigators to bring novel combination regimens to patients with advanced colorectal cancer.